Status:
COMPLETED
Multiple Dose Study Evaluating the Safety and Tolerability of NSA-789
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Conditions:
Alzheimer Disease
Healthy Subjects
Eligibility:
All Genders
18-99 years
Phase:
PHASE1
Brief Summary
This is a multiple dose study of NSA-789, the purpose of which is to assess the safety and tolerability in healthy subjects and subjects with Alzheimer's Disease
Eligibility Criteria
Inclusion
- Inclusion Criteria
- Men or women aged 18 - 50 years (healthy subjects) or greater than 55 years old (subjects with Alzheimer's Disease)
- Women must be surgically sterile or postmenopausal
- Subjects with Alzheimer's Disease must be generally healthy, but may have a stable, chronic illness if well controlled.
- Exclusion Criteria
- Healthy subjects may not be on any prescription or investigation drugs within 30 days of start of study.
- Subjects with Alzheimer's Disease may not be on any cholinesterase inhibitors such as donepezil (Aricept®) or rivastigmine (Exelon®) within 4 weeks of the start of the study.
Exclusion
Key Trial Info
Start Date :
January 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2009
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT00795730
Start Date
January 1 2009
End Date
May 1 2009
Last Update
August 20 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Glendale, California, United States, 91206